Antiretroviral therapy (ART) for HIV is vulnerable to unplanned treatment interruptions–consecutively missed doses over a series of days–which can result in virologic rebound. Yet clinicians lack a si
BACKGROUND: The identification of poor medicinal adherence is difficult because direct observation of medication use is usually impractical. Up to 50% of individuals on chronic therapies may not be ta
Association between experiencing side effects of artesunate/amodiaquine malaria chemoprevention (ASAQ-CP) in the first round of mass drug administration (MDA) with initiation of ASAQ-CP in the second
